Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide

被引:41
作者
Delgado, M [1 ]
Leceta, J
Abad, C
Martinez, C
Ganea, D
Gomariz, RP
机构
[1] Univ Complutense, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain
[2] Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA
关键词
neuropeptides; CD14; inflammation; lipopolysaccharide; neuroimmunomodulation;
D O I
10.1016/S0165-5728(99)00105-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Macrophage activation and deactivation play essential roles in the initiation and maintenance of a successful immune response. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP), two structurally related neuropeptides, act as macrophage deactivating factors. We reported previously that VIP and PACAP inhibit IL-6, IL,-12, TNF alpha and NO production, and enhance IL-10 production, from lipopolysaccharide (LPS)-stimulated macrophages. In this study, we demonstrate that VIP and PACAP down-regulate the expression of CD14, the membrane-bound LPS receptor, by inducing its rapid shedding. The soluble CD14 released by VIP and PACAP corresponds in size to the soluble CD14 released by PMA. Neither VIP/PACAP nor PMA, affect the steady-state levels of CD14 mRNA. The CD14 shedding induced by VIP/PACAP is mediated through the PAC1 specific receptors and the major transduction pathway involves the protein kinase C (PKC). The VIP/PACAP inhibition of TNF alpha( and NO occurs through both CD14-dependent and -independent mechanisms, whereas the inhibition of IL,-6 production appears to be strictly CD14-dependent. The shedding of CD14 by VIP and PACAP represents an important mechanism by which these neuropeptides limit the macrophage inflammatory response. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:61 / 71
页数:11
相关论文
共 48 条
  • [1] BAZIL V, 1991, J IMMUNOL, V147, P1567
  • [2] Bozza M, 1998, EUR J IMMUNOL, V28, P3120, DOI 10.1002/(SICI)1521-4141(199810)28:10<3120::AID-IMMU3120>3.0.CO
  • [3] 2-3
  • [4] COSENTINO G, 1995, J IMMUNOL, V155, P3145
  • [5] Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun
    Delgado, M
    Munoz-Elias, EJ
    Kan, YQ
    Gozes, I
    Fridkin, M
    Brenneman, DE
    Gomariz, RP
    Ganea, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (47) : 31427 - 31436
  • [6] Delgado M, 1999, J IMMUNOL, V162, P4685
  • [7] Delgado M, 1999, J IMMUNOL, V162, P2358
  • [8] Delgado M, 1999, J IMMUNOL, V162, P1707
  • [9] VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages.: Subsequent effect on IFNγ synthesis by T cells
    Delgado, M
    Munoz-Elias, EJ
    Gomariz, RP
    Ganea, D
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1999, 96 (02) : 167 - 181
  • [10] Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages
    Delgado, M
    Pozo, D
    Martinez, C
    Garrido, E
    Leceta, J
    Calvo, JR
    Gomariz, RP
    [J]. REGULATORY PEPTIDES, 1996, 62 (2-3) : 161 - 166